ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "drug therapy"

  • Abstract Number: 107 • 2016 ACR/ARHP Annual Meeting

    Improvement of Quality and Cost-Effectiveness of Rheumatology Care By Creating Long-Term Alliances with Pharmaceutical Companies

    M Van Houdenhoven (CEO, PhD, Prof)1, F.H.J. van den Hoogen (MD, PhD, Prof)2, K Bevers (MD, PhD)2, W.H. van der Laan (MD, PhD)2, J Van der Werf2, M Staub3 and B.J.F. Van den Bemt (PharmD, PhD)4, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 3Purchasing department, Sint Maartenskliniek, Nijmegen, Netherlands, 4Department of Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose:  Biological therapies have importantly contributed to controlling disease activity in patients with inflammatory rheumatic diseases. As the high costs of biologics are a threat…
  • Abstract Number: 3088 • 2015 ACR/ARHP Annual Meeting

    Genome Wide Expression Analyses Reveal Potentially Novel Drug Targets in Fibromyalgia

    Kim Jones1, Robert Bennett2,3 and Sunil Kurian4, 1Rsch & Develop/Mail Code SN OR, Oregon Health Sciences Univ, Portland, OR, 2SN-Office of Research & Development, Oregon Health & Science Univ, Portland, OR, 3Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, 4The Scripps Research Institute, La Jolla, CA

    Background/Purpose: Currently there are three drugs approved by the FDA for the treatment of fibromyalgia (FM), and there appears to be a paucity of drugs…
  • Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting

    Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis

    Masao Sato1 and Masao Takemura2, 1Rheumatology, Matsunami General Hospital, Gifu, Japan, 2Matsunami Reserch Park, Gifu, Japan

    Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
  • Abstract Number: 2362 • 2014 ACR/ARHP Annual Meeting

    Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model

    Rebecca A. Bader, David R. Wilson, Arundhati Ramani and Patricia R. Wardwell, Biomedical & Chemical Engineering, Syracuse University, Syracuse, NY

    Background/Purpose:  A number of conventional, disease modifying anti-rheumatic drugs (DMARDs) are associated with severe side effects due to non-specific targeting and impaired immune function. To…
  • Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting

    Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis

    Doquyen H. Huynh1, Carol J. Etzel2,3, Vanessa Cox4, Philip J. Mease5 and Arthur Kavanaugh6, 1Rheumatology, UC San Diego School of Medicine, San Diego, CA, 2PO Box 786, Corrona, LLC., Southborough, MA, 3Department of Epidemiology, UT MD Anderson, Houston, TX, 4CORRONA, Inc, Southborough, MA, 5CORRONA, Seattle, WA, 6UCSD School of Medicine, La Jolla, CA

    Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…
  • Abstract Number: 636 • 2014 ACR/ARHP Annual Meeting

    Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE

    Yaakov Naparstek1, Eli Moallem2, Rina Ulmansky3, Erez Koren3 and Yechezkel Barenholz3, 1Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, 2Dept. of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, 3Hadassah - Hebrew University Medical Center, Jerusalem, Israel

    Background/Purpose Glucocorticoids (GCs) have been known for years to be the most effective therapy in SLE. Their use is however limited by the need of…
  • Abstract Number: 1731 • 2013 ACR/ARHP Annual Meeting

    Treatment Of Innate Immune Arthritis With a Toll-Like Receptor 7 Agonist Requires Type I Interferon

    Maripat Corr1, Tomoko Hayashi2, Dennis A. Carson3, Howard Cottam4 and Joshua Yang3, 1Medicine, Univ of California-San Diego, La Jolla, CA, 2Medicine, UCSD School of Medicine, La Jolla, CA, 3UCSD School of Medicine, La Jolla, CA, 4ucsd School of Medicine, La Jolla, CA

    Background/Purpose: We previously demonstrated that repeated administration of the low molecular weight Toll-like receptor (TLR) 7 agonist (1V136) substantially reduces arthritic inflammation in mice.  Here…
  • Abstract Number: 1707 • 2013 ACR/ARHP Annual Meeting

    Biological Insights From Genetics Of Rheumatoid Arthritis Contribute To Drug Discovery

    Yukinori Okada1,2,3, Di Wu2,4,5,6, Chikashi Terao7,8, Katsunori Ikari9, Yuta Kochi10, Koichiro Ohmura11, Akari Suzuki10, Hisashi Yamanaka9, Joshua C. Denny12, Jeffrey D. Greenberg13, Robert R. Graham14, Matthew A. Brown15, Sang-Cheol Bae16, Jane Worthington17, Leonid Padyukov18, Lars Klareskog19, Peter K. Gregersen20, Peter M. Visscher21,22, Katherine A. Siminovitch23,24 and Robert M. Plenge25, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 3Broad Institute, Cambridge, MA, 4Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, 5Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, 6Department of Statistics, Harvard University, Cambridge, MA, 7Center for Genomic Medicine, Kyoto University, Kyoto, Japan, 8Department of Rheumatology and Clinical immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 9Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 10Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, 11Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 12Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, 13Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 14ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, 15Human Genetics Group, The University of Queensland Diamantina Insititute, Brisbane, Australia, 16Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 17Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 18Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 19Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 20Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 21The University of Queensland Diamantina Institute, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia, 22Queensland Brain Institute, The University of Queensland, St Lucia, Brisbane, Australia, 23Mount Sinai Hospital, Toronto, ON, Canada, 24University of Toronto, Toronto, ON, Canada, 25Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological datasets to provide…
  • Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting

    Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice

    Glenn Haugeberg1, Andreas P. Diamantopoulos1, Agnete Gulati2, Mari Hoff3 and Arthur Kavanaugh4, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Rheumatology, St.Olavs Hospital, Trondheim, Norway, 3Rheumatology, St Olavs Hospital, Trondheim, Norway, 4University of California San Diego, San Diego, CA

    Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…
  • Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting

    The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries

    Axel Finckh1, Florenzo Iannone2, Juan Gomez Reino3, David Neto4, Elisabeth Lie5, Piet van Riel6, Merete Lund Hetland7, Karel Pavelka8, Carl Turesson9, Xavier Mariette10 and Jacques-Eric Gottenberg11, 1Department of Medical Specialities, University of Geneva, Geneva, Switzerland, 2D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, 3Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, 4Rheumatology, University of Geneva, Geneva, Switzerland, 5Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 6Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 7Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 8Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 9Lund University, Malmö, Sweden, 10Paris-Sud University, Paris, France, 11Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France

    Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…
  • Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting

    Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio

    Bente Glintborg1,2, Bjorn Gudbjornsson3,4, Niels Steen Krogh5, Emina Omerovic2, Natalia Manilo6, Mette Holland-Fischer7, Hanne M. Lindegaard8, Anne Gitte Loft9, Henrik Nordin10, Laura Johnsen11, Sussi Flejsborg Oeftiger12, Annette Hansen13, Claus Rasmussen14, Gerdur Grondal15, Árni Jón Geirsson16 and Merete Lund Hetland1,2,17, 1The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 3Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, 4Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 5ZiteLab ApS, Copenhagen, Denmark, 6Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, 7Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, 9Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, 10Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, 11Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, 12Department of Rheumatology, Køge Hospital, Køge, East Timor, 13Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, 14Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, 15Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 16Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 17Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark

    Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
  • Abstract Number: 1595 • 2012 ACR/ARHP Annual Meeting

    Genome-Wide Association Study to High -Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling

    Gang Li1, Dorothee Diogo2, Di Wu1, Jim Spoonamore3, Rheumatoid Arthritis Consortium International (RACI)4, Eli Stahl5, Nicola Tolliday3 and Robert M. Plenge6, 1Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 3Broad Institute, Cambridge, MA, 4Boston, 5Brigham and Women's Hospital, 6Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Deriving therapeutic targets from human genetics linked with biological alterations of risk alleles may provide a more successful approach to drug development than traditional…
  • Abstract Number: 1149 • 2012 ACR/ARHP Annual Meeting

    Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)

    Kirsten Minden1, Martina Niewerth2, Jens Klotsche3, Michael Hammer4, Johannes Peter Haas5, Gerd Ganser6 and Gerd Horneff7, 1Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany, 2Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 3Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, 4Klinik fuer Rheumatologie, St. Josef-Stift, Sendenhorst, Germany, 5German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 6Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, 7Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany

    Background/Purpose: Etanercept (Eta) has been the most frequently used biologic drug in patients with JIA. In Germany, about one in three patients with polyarticular JIA…
  • Abstract Number: 802 • 2012 ACR/ARHP Annual Meeting

    Milnacipran Reduces Brain Activity During Pain in Fibromyalgia

    Anson E. Kairys1, Richard E. Harris2, Eric Ichesco2, Johnson P. Hampson2, Steven Harte2, Daniel J. Clauw3 and Tobias Schmidt-Wilcke2, 1Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, 2Anesthesiology, University of Michigan, Ann Arbor, MI, 3Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI

    Background/Purpose: Fibromyalgia (FM) is a chronic pain condition characterized by widespread musculoskeletal pain and a number of concomitant symptoms such as fatigue, sleep disturbance, cognitive…
  • Abstract Number: 805 • 2012 ACR/ARHP Annual Meeting

    Milnacipran Increases Cortical to Brainstem Connectivity During Pain in Fibromyalgia

    Eric Ichesco1, Tobias Schmidt-Wilcke1, Anson E. Kairys2, Johnson P. Hampson1, Steven E. Harte1, Daniel J. Clauw3 and Richard E. Harris1, 1Anesthesiology, University of Michigan, Ann Arbor, MI, 2Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, 3Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI

    Background/Purpose: Fibromyalgia (FM) is a chronic widespread pain disorder characterized by muscle tenderness, fatigue, poor sleep, and mood disturbance.  Milnacipran is a dual serotonin-norepinephrine reuptake…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology